"The American Society of Clinical Oncology (ASCO) has updated their antiemetic guideline to include the use of a novel antiemetic combination for cancer patients. The update was published in the Journal of Clinical Oncology.
Based on results of a phase III clinical trial, the guideline authors now recommend the use of the oral combination of the neurokinin 1 (NK1) receptor antagonist netupitant, the 5-hydroxytryptamine-3 (5-HT3) receptor antagonist palonosetron, and dexamethasone to prevent acute and delayed nausea and vomiting for patients being treated with highly emetogenic chemotherapy regimens.":
Good news for our American members struggling with nausea and vomiting during chemotherapy treatment; hopefully other countries will update their guidelines accordingly.